Baird analyst Michael Ulz reiterated an Outperform rating and $22 price target on Karyopharm Therapeutics (NASDAQ: KPTI) saying momentum building ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE